Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bicara Therapeutics Inc (BCAX)

Bicara Therapeutics Inc (BCAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,536,511
  • Shares Outstanding, K 65,467
  • Annual Sales, $ 0 K
  • Annual Income, $ -137,950 K
  • EBIT $ -156 M
  • EBITDA $ -155 M
  • 60-Month Beta -1.23
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.28

Options Overview Details

View History
  • Implied Volatility 84.74% (+4.66%)
  • Historical Volatility 42.12%
  • IV Percentile 4%
  • IV Rank 18.42%
  • IV High 321.03% on 09/26/25
  • IV Low 31.38% on 09/08/25
  • Expected Move (DTE 24) 1.19 (5.15%)
  • Put/Call Vol Ratio 55.00
  • Today's Volume 56
  • Volume Avg (30-Day) 89
  • Put/Call OI Ratio 2.26
  • Today's Open Interest 3,740
  • Open Int (30-Day) 3,410
  • Expected Range 21.92 to 24.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.64
  • Number of Estimates 6
  • High Estimate $-0.57
  • Low Estimate $-0.66
  • Prior Year $-0.68
  • Growth Rate Est. (year over year) +5.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.63 +31.08%
on 03/30/26
24.25 -4.70%
on 04/17/26
+4.70 (+25.53%)
since 03/20/26
3-Month
13.75 +68.07%
on 02/17/26
24.25 -4.70%
on 04/17/26
+6.14 (+36.18%)
since 01/21/26
52-Week
7.80 +196.28%
on 05/23/25
24.25 -4.70%
on 04/17/26
+10.46 (+82.69%)
since 04/21/25

Most Recent Stories

More News
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients...

BCAX : 23.11 (-1.53%)
Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Selected 1500mg weekly of ficerafusp alfa as the optimal dose and initiated Phase 3 of the FORTIFI-HN01 pivotal trial; interim analysis expected mid-2027 Announced development of a less frequent loading...

BCAX : 23.11 (-1.53%)
Bicara Has a Cancer Drug Wall Street Is Starting to Believe In. Earnings Will Tell Us If That Faith Is Earned.

Barchart Research What to Expect from BCAX Earnings BCAX Generated March 27, 2026 Current Price $18.37 EPS Estimate $-0.72 Consensus Rating Strong Buy Average Move 5.47% Bicara Has a Cancer Drug Wall Street...

BCAX : 23.11 (-1.53%)
Bicara Has a Cancer Drug Wall Street Is Starting to Believe In. Earnings Will Tell Us If That Faith Is Earned.

Barchart Research What to Expect from BCAX Earnings BCAX Generated March 27, 2026 Current Price $18.37 EPS Estimate $-0.72 Consensus Rating Strong Buy Average Move 5.47% Bicara Has a Cancer Drug Wall Street...

BCAX : 23.11 (-1.53%)
Bicara Has a Cancer Drug Wall Street Is Starting to Believe In. Earnings Will Tell Us If That Faith Is Earned.

Barchart Research What to Expect from BCAX Earnings BCAX Generated March 27, 2026 Current Price $18.37 EPS Estimate $-0.72 Consensus Rating Strong Buy Average Move 5.47% Bicara Has a Cancer Drug Wall Street...

BCAX : 23.11 (-1.53%)
Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET

BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients...

BCAX : 23.11 (-1.53%)
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients...

BCAX : 23.11 (-1.53%)
Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with...

BCAX : 23.11 (-1.53%)
Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants

BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with...

BCAX : 23.11 (-1.53%)
Bicara Therapeutics Announces Proposed Public Offering of Common Stock

BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with...

BCAX : 23.11 (-1.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. The company's lead asset includes ficerafusp alfa. Bicara Therapeutics Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 24.62
2nd Resistance Point 24.08
1st Resistance Point 23.60
Last Price 23.11
1st Support Level 22.58
2nd Support Level 22.04
3rd Support Level 21.56

See More

52-Week High 24.25
Last Price 23.11
Fibonacci 61.8% 17.97
Fibonacci 50% 16.02
Fibonacci 38.2% 14.08
52-Week Low 7.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.